Pathos AI
Also known as Pathos, Pathos AI, Inc.
Licenses clinical-stage drugs from other companies and develops them itself, using an agent platform (Foundry, earlier PathOS) trained on patient records to choose assets, pick the patients most likely to respond and adjust trials as they run. Its pipeline is in cancer: prostate cancer, multiple myeloma, lung and breast cancer and TROP2/HER3-expressing solid tumours; in October 2026 it began work in Alzheimer's disease with Bristol Myers Squibb and Tempus.
Money and evidence
No research by this company is on the record yet.
Rounds and research, on one timeline
- 2026-10-23Series ERound
$237M$3B post · stated by company
For: To scale the Foundry platform and advance its pipeline: JSKN016, a TROP2/HER3 bispecific antibody-drug conjugate, toward registrational studies, plus pocenbrodib in prostate cancer and multiple myeloma, AZD4241 with AstraZeneca and DO-2.
Models and platformToward the clinic
The company's release says the round closed at a post-money valuation of about $3B, led by Bristol Myers Squibb with existing investors it does not name. A second release the same day sets out the BMS and Tempus collaborations that came with it.
On the deal: Simon Davies (SVP, Head of Data and Quantitative Sciences; spoke for the lead in the announcement, Bristol Myers Squibb)
- 2025-05-15Series DRound
$365M$1.6B post · stated by company
For: To advance its clinical-stage pipeline and keep building its AI foundation model for oncology, which it calls the largest multimodal one in the field.
Models and platformToward the clinic
Read in the company's GlobeNewswire release as reposted on its funding page; the part read names no investor.
No investor named in the source.
- 2024-10-29Series CRound
$62M$600M post · stated by company
For: To grow its team of scientists and engineers, develop the AI drug-development platform and advance its clinical-stage cancer pipeline.
HiringModels and platformToward the clinic
The company's release, dated Chicago, calls the round oversubscribed and says it brought total funding to $102M. Mohamad Makhzoumi of NEA spoke for the lead.
Lead · NEARevolution GrowthExisting investor · LightbankExisting investor · Builders VC
On the deal: Mohamad Makhzoumi (Co-CEO; spoke for the lead in the announcement, NEA)
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.
Its investors also backed
Other companies on this page whose rounds name the same investor.
- Bristol Myers SquibbBigHat Biosciences, Owkin
- NEAXaira Therapeutics, CuspAI